Innocan Pharma Announces First Tranche Closing of Private Placement of Units
Image File
Original HTML

HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September 9, 2026, it has complete a private placement of 247,314 units of the Company (the "Units") at a price of C$1.87 per Unit for gross proceeds of C$462,477 (the "Offering").

Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a "Common Share"); and (ii) one (1) common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C$2.50 for a period of three (3) years from the date of issuance; provided that following issuance of the Warrants, if the daily volume weighted average trading price of the Common Shares on the Canadian Securities Exchange for 30 consecutive trading days equals or exceeds $4.80, the Company can, on written notice to the subscribers or by press release (the "Acceleration Notice") accelerate the expiry date of the Warrants to the date that is 30 days following the date of the Acceleration Notice.

Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes. Innocan also paid a finder's fee equal to 10% in cash and issued 8% finder's warrants to arm's length finders.

The securities issued to subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws and the policies of the Canadian Securities Exchange.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or "U.S. Persons", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About Innocan

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.

www.innocanpharma.com 

For further information, please contact:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+ 15162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions relating to the Offering, including the terms, timing, potential completion, and the use of proceeds of the Offering.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: the ability of the Company to satisfy the conditions of closing of future tranches of the Offering; that further tranches of the Offering may not be completed on the terms and timeline indicated, or at all; that the Company's use of proceeds of the Offering may differ from those indicated; global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public disclosure and filings which are available under Innocan's profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg

SOURCE Innocan Pharma Corporation

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302888171
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): TARGET contains an inaccurate material claim: it states C$4.80 is 'more than double the current warrant strike price' of C$2.50, but C$4.80 is 1.92x the strike price, not more than double. It also characterizes the acceleration threshold as 'if shares triple in value,' while C$4.80 is only about 2.57x the C$1.87 issue price.
Source Name
Unknown Company
Original Summary

<p>HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September 9, 2026, it has complete a private placement of 247,314...</p>

Original Link
Original Source
Image URL
https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg?p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Innocan Pharma Closes C$462,477 Private Placement With Warrant Accelerator", "body_html": "<p><strong>Herzliya, Israel -- [CURRENT_DATE] --</strong> Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has closed a private placement of 247,314 units at C$1.87 apiece, raising gross proceeds of C$462,477 for working capital and general corporate purposes.</p><h5>Each unit pairs a common share with a three-year warrant priced above market</h5><p>Every unit sold consists of one common share and one warrant exercisable at C$2.50, roughly 34% above the C$1.87 issue price. The warrants run for three years from issuance.</p><h5>Company can force early exercise if shares triple in value</h5><p>Innocan retains the right to accelerate the warrant expiry to 30 days after issuing an acceleration notice if the 30-day volume-weighted average trading price on the Canadian Securities Exchange hits or exceeds C$4.80 -- more than double the current warrant strike price.</p><h5>Finders collected 10% cash and 8% in warrants on the deal</h5><p>Innocan paid arm's-length finders a 10% cash fee plus finder's warrants equal to 8% of the placement, a standard structure for small-cap Canadian financings. Securities issued to subscribers carry a statutory hold period of four months and one day under Canadian securities law and CSE policy.</p><h5>Financing follows a September 9 announcement of the same offering</h5><p>The closing confirms terms first disclosed in Innocan's September 9, 2026 press release. The securities have not been registered under the U.S. Securities Act and cannot be offered or sold to U.S. persons absent registration or an applicable exemption.</p>", "meta_description": "Innocan Pharma closes a C$462,477 private placement of 247,314 units at C$1.87, with warrants exercisable at C$2.50 and an early-acceleration clause.", "seo_keywords": "Innocan Pharma, private placement, CSE INNO, warrant financing, Canadian Securities Exchange, small-cap financing, working capital", "companies": ["Innocan Pharma Corporation"], "industries": ["Biopharmaceuticals"], "markets_regions": ["Canada", "Global"], "news_type": ["financial_disclosure"], "themes": ["capital_markets"], "products": [], "events": [], "cta_text": "Details on the offering terms and warrant structure are available in Innocan's regulatory filings.", "learn_more": "https://www.innocanpharma.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
bdcf57f32bac8f2c86d28cdc9ccec56c